PSYENCE BIOMEDICAL LTD. Form SCHEDULE 13D/A — Oct 15, 2026
Psyence Labs Ltd. filed Amendment No. 1 to its Schedule 13D on Psyence Biomedical Ltd., disclosing it acquired 1,497,500 additional common shares on October 1, 2026 under a Share-for-Share Swap and Nomination Agreement dated September 21, 2026. The shares were issued at a deemed price of US$6.00 per share for non-cash consideration of US$8,985,000, with PsyLabs issuing 3,473 of its own shares to issuer subsidiary Psyence Biomed II Corp.
Key figures
- Shares Outstanding
- 5314048
- Percent owned
- 49.75%
- Subject shares prior
- 1146159
- Deemed issue price usd
- 6
- Additional shares issued
- 1497500
- Psylabs implied valuation usd
- 60000000
- Psylabs shares issued to pbcii
- 3473
- Approved investment by issuer usd
- 5000000
- Total beneficial ownership shares
- 2643659
- Aggregate non cash consideration usd
- 8985000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.